The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH Erythro 2025 | Mitapivat: mechanism of action and updates with this agent in thalassemia treatment
In this video, Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, briefly discusses the potential of mitapivat in treating thalassemia, citing the promising results of the ENERGIZE and ENERGIZE-T clinical trials (NCT04770753; NCT04770779), which have shown impressive benefits. Prof. Cappellini suggests that mitapivat may be combined with luspatercept in the future to improve treatment outcomes. This interview took place at the 4th ESH Translational Research Conference on Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia in Dublin, Ireland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
